REPLIGEN CORP (RGEN) Stock Fundamental Analysis
USA - NASDAQ:RGEN - US7599161095 - Common Stock
145.66 USD
+2.84 (+1.99%)
145.66 USD
0 (0%)
Taking everything into account, RGEN scores 5 out of 10 in our fundamental rating. RGEN was compared to 58 industry peers in the Life Sciences Tools & Services industry. RGEN has an excellent financial health rating, but there are some minor concerns on its profitability. RGEN is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
RGEN had positive earnings in the past year.
In the past year RGEN had a positive cash flow from operations.
RGEN had positive earnings in 4 of the past 5 years.
Each year in the past 5 years RGEN had a positive operating cash flow.
1.2 Ratios
Looking at the Return On Assets, with a value of -0.48%, RGEN is in the better half of the industry, outperforming 63.79% of the companies in the same industry.
Looking at the Return On Equity, with a value of -0.67%, RGEN is in the better half of the industry, outperforming 65.52% of the companies in the same industry.
RGEN has a Return On Invested Capital (0.57%) which is comparable to the rest of the industry.
RGEN had an Average Return On Invested Capital over the past 3 years of 2.65%. This is significantly below the industry average of 13.58%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -0.48% | ||
| ROE | -0.67% | ||
| ROIC | 0.57% |
ROA(3y)2.57%
ROA(5y)3.26%
ROE(3y)3.42%
ROE(5y)4.3%
ROIC(3y)2.65%
ROIC(5y)3.3%
1.3 Margins
RGEN has a Operating Margin of 3.72%. This is comparable to the rest of the industry: RGEN outperforms 58.62% of its industry peers.
In the last couple of years the Operating Margin of RGEN has declined.
RGEN has a Gross Margin (50.99%) which is comparable to the rest of the industry.
RGEN's Gross Margin has declined in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 3.72% | ||
| PM (TTM) | N/A | ||
| GM | 50.99% |
OM growth 3Y-58.46%
OM growth 5Y-32.3%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-4.88%
GM growth 5Y-2.12%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so RGEN is destroying value.
The number of shares outstanding for RGEN has been increased compared to 1 year ago.
RGEN has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, RGEN has an improved debt to assets ratio.
2.2 Solvency
An Altman-Z score of 6.59 indicates that RGEN is not in any danger for bankruptcy at the moment.
RGEN has a better Altman-Z score (6.59) than 86.21% of its industry peers.
The Debt to FCF ratio of RGEN is 5.04, which is a neutral value as it means it would take RGEN, 5.04 years of fcf income to pay off all of its debts.
RGEN's Debt to FCF ratio of 5.04 is fine compared to the rest of the industry. RGEN outperforms 70.69% of its industry peers.
A Debt/Equity ratio of 0.26 indicates that RGEN is not too dependend on debt financing.
RGEN has a Debt to Equity ratio (0.26) which is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.26 | ||
| Debt/FCF | 5.04 | ||
| Altman-Z | 6.59 |
ROIC/WACC0.06
WACC9.91%
2.3 Liquidity
RGEN has a Current Ratio of 8.59. This indicates that RGEN is financially healthy and has no problem in meeting its short term obligations.
RGEN's Current ratio of 8.59 is amongst the best of the industry. RGEN outperforms 89.66% of its industry peers.
RGEN has a Quick Ratio of 7.32. This indicates that RGEN is financially healthy and has no problem in meeting its short term obligations.
RGEN has a better Quick ratio (7.32) than 89.66% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 8.59 | ||
| Quick Ratio | 7.32 |
3. Growth
3.1 Past
RGEN shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 21.17%, which is quite impressive.
The Earnings Per Share has been growing slightly by 7.11% on average over the past years.
Looking at the last year, RGEN shows a decrease in Revenue. The Revenue has decreased by -8.54% in the last year.
Measured over the past years, RGEN shows a quite strong growth in Revenue. The Revenue has been growing by 18.62% on average per year.
EPS 1Y (TTM)21.17%
EPS 3Y-21.5%
EPS 5Y7.11%
EPS Q2Q%6.98%
Revenue 1Y (TTM)-8.54%
Revenue growth 3Y-1.83%
Revenue growth 5Y18.62%
Sales Q2Q%21.94%
3.2 Future
RGEN is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 25.53% yearly.
Based on estimates for the next years, RGEN will show a quite strong growth in Revenue. The Revenue will grow by 15.90% on average per year.
EPS Next Y15.05%
EPS Next 2Y20.45%
EPS Next 3Y23%
EPS Next 5Y25.53%
Revenue Next Year15.25%
Revenue Next 2Y13.99%
Revenue Next 3Y14.29%
Revenue Next 5Y15.9%
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings ratio is 87.75, which means the current valuation is very expensive for RGEN.
RGEN's Price/Earnings ratio is in line with the industry average.
Compared to an average S&P500 Price/Earnings ratio of 26.28, RGEN is valued quite expensively.
RGEN is valuated quite expensively with a Price/Forward Earnings ratio of 67.84.
The rest of the industry has a similar Price/Forward Earnings ratio as RGEN.
Compared to an average S&P500 Price/Forward Earnings ratio of 33.61, RGEN is valued quite expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 87.75 | ||
| Fwd PE | 67.84 |
4.2 Price Multiples
RGEN's Enterprise Value to EBITDA is on the same level as the industry average.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of RGEN is on the same level as its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 77.35 | ||
| EV/EBITDA | 78.71 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
A more expensive valuation may be justified as RGEN's earnings are expected to grow with 23.00% in the coming years.
PEG (NY)5.83
PEG (5Y)12.35
EPS Next 2Y20.45%
EPS Next 3Y23%
5. Dividend
5.1 Amount
No dividends for RGEN!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
145.66
+2.84 (+1.99%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)
Earnings (Next)
Inst Owners98.43%
Inst Owner Change-1.41%
Ins Owners0.5%
Ins Owner Change-2.37%
Market Cap8.19B
Revenue(TTM)707.89M
Net Income(TTM)-13.83M
Analysts80.71
Price Target181.69 (24.74%)
Short Float %6.44%
Short Ratio3.79
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)1.95%
Min EPS beat(2)-6.83%
Max EPS beat(2)10.73%
EPS beat(4)3
Avg EPS beat(4)8.75%
Min EPS beat(4)-6.83%
Max EPS beat(4)25.89%
EPS beat(8)4
Avg EPS beat(8)7.57%
EPS beat(12)8
Avg EPS beat(12)8.61%
EPS beat(16)12
Avg EPS beat(16)12.23%
Revenue beat(2)2
Avg Revenue beat(2)1.69%
Min Revenue beat(2)1.23%
Max Revenue beat(2)2.15%
Revenue beat(4)2
Avg Revenue beat(4)0.11%
Min Revenue beat(4)-2.03%
Max Revenue beat(4)2.15%
Revenue beat(8)2
Avg Revenue beat(8)-0.75%
Revenue beat(12)3
Avg Revenue beat(12)-0.94%
Revenue beat(16)7
Avg Revenue beat(16)0.86%
PT rev (1m)0.06%
PT rev (3m)-1.05%
EPS NQ rev (1m)1%
EPS NQ rev (3m)1.21%
EPS NY rev (1m)-0.74%
EPS NY rev (3m)-0.64%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0.37%
Revenue NY rev (1m)0.63%
Revenue NY rev (3m)2.95%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 87.75 | ||
| Fwd PE | 67.84 | ||
| P/S | 12.16 | ||
| P/FCF | 77.35 | ||
| P/OCF | 62.03 | ||
| P/B | 3.97 | ||
| P/tB | 15.13 | ||
| EV/EBITDA | 78.71 |
EPS(TTM)1.66
EY1.14%
EPS(NY)2.15
Fwd EY1.47%
FCF(TTM)1.88
FCFY1.29%
OCF(TTM)2.35
OCFY1.61%
SpS11.98
BVpS36.65
TBVpS9.63
PEG (NY)5.83
PEG (5Y)12.35
Graham Number37
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -0.48% | ||
| ROE | -0.67% | ||
| ROCE | 0.9% | ||
| ROIC | 0.57% | ||
| ROICexc | 0.76% | ||
| ROICexgc | 2.86% | ||
| OM | 3.72% | ||
| PM (TTM) | N/A | ||
| GM | 50.99% | ||
| FCFM | 15.72% |
ROA(3y)2.57%
ROA(5y)3.26%
ROE(3y)3.42%
ROE(5y)4.3%
ROIC(3y)2.65%
ROIC(5y)3.3%
ROICexc(3y)3.74%
ROICexc(5y)4.93%
ROICexgc(3y)17.96%
ROICexgc(5y)N/A
ROCE(3y)4.23%
ROCE(5y)5.26%
ROICexgc growth 3Y-71.22%
ROICexgc growth 5Y-37.94%
ROICexc growth 3Y-63.64%
ROICexc growth 5Y-32.38%
OM growth 3Y-58.46%
OM growth 5Y-32.3%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-4.88%
GM growth 5Y-2.12%
F-Score4
Asset Turnover0.23
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.26 | ||
| Debt/FCF | 5.04 | ||
| Debt/EBITDA | 5.34 | ||
| Cap/Depr | 34.97% | ||
| Cap/Sales | 3.88% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 132.29% | ||
| Profit Quality | N/A | ||
| Current Ratio | 8.59 | ||
| Quick Ratio | 7.32 | ||
| Altman-Z | 6.59 |
F-Score4
WACC9.91%
ROIC/WACC0.06
Cap/Depr(3y)91.1%
Cap/Depr(5y)111.21%
Cap/Sales(3y)7.3%
Cap/Sales(5y)7.94%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)21.17%
EPS 3Y-21.5%
EPS 5Y7.11%
EPS Q2Q%6.98%
EPS Next Y15.05%
EPS Next 2Y20.45%
EPS Next 3Y23%
EPS Next 5Y25.53%
Revenue 1Y (TTM)-8.54%
Revenue growth 3Y-1.83%
Revenue growth 5Y18.62%
Sales Q2Q%21.94%
Revenue Next Year15.25%
Revenue Next 2Y13.99%
Revenue Next 3Y14.29%
Revenue Next 5Y15.9%
EBIT growth 1Y451.21%
EBIT growth 3Y-59.22%
EBIT growth 5Y-19.7%
EBIT Next Year75.45%
EBIT Next 3Y40.62%
EBIT Next 5Y36%
FCF growth 1Y10.02%
FCF growth 3Y45.03%
FCF growth 5Y27.02%
OCF growth 1Y-11.28%
OCF growth 3Y13.8%
OCF growth 5Y21.15%
REPLIGEN CORP / RGEN FAQ
Can you provide the ChartMill fundamental rating for REPLIGEN CORP?
ChartMill assigns a fundamental rating of 5 / 10 to RGEN.
What is the valuation status of REPLIGEN CORP (RGEN) stock?
ChartMill assigns a valuation rating of 2 / 10 to REPLIGEN CORP (RGEN). This can be considered as Overvalued.
What is the profitability of RGEN stock?
REPLIGEN CORP (RGEN) has a profitability rating of 4 / 10.
What is the valuation of REPLIGEN CORP based on its PE and PB ratios?
The Price/Earnings (PE) ratio for REPLIGEN CORP (RGEN) is 87.75 and the Price/Book (PB) ratio is 3.97.
Can you provide the expected EPS growth for RGEN stock?
The Earnings per Share (EPS) of REPLIGEN CORP (RGEN) is expected to grow by 15.05% in the next year.